Two Firms Race To Derive Profits From Mussels' Glue

Despite gaps in their knowledge of how the mollusk produces the adhesive, scientists hope to re-create it GAITHERSBURG, MD. -- "Nature didn't make mussel glue for man's instant gratification," says Herbert Waite, the marine biochemist who first isolated adhesive protein from the foot of the common blue mussel. But man certainly intends to make use of and profit from this novel material. Last month, Genex Corp. - a Maryland biotechnology company - introduced its first glue based on the mussel

Written byDiana Morgan
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share


Despite gaps in their knowledge of how the mollusk produces the adhesive, scientists hope to re-create it
GAITHERSBURG, MD. -- "Nature didn't make mussel glue for man's instant gratification," says Herbert Waite, the marine biochemist who first isolated adhesive protein from the foot of the common blue mussel. But man certainly intends to make use of and profit from this novel material.

Last month, Genex Corp. - a Maryland biotechnology company - introduced its first glue based on the mussel adhesive. A second firm, BioPolymers Corp. of Farmington, Conn., has just gotten a patent on a synthetic version of the glue. But, Waite feels, neither firm will be able to take full advantage of this new glue until it better understands how the mussel makes the adhesive in the first place.

It took years for Waite, at the University of Delaware, to obtain the natural protein. And it may take ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies